Sofocure – L Tab

### Sofocure-L Capsule **PRODUCT DESCRIPTION:** Sofocure-L is a fixed-dose combination antiviral medication that contains Ledipasvir and Sofosbuvir, indicated for the treatment of chronic hepatitis C virus (HCV) infection. **ACTIVE INGREDIENTS:** – **Ledipasvir (90 mg)**: An NS5A inhibitor that prevents the virus from replicating and assembling within the host’s liver cells. – **Sofosbuvir (400 mg)**: An NS5B polymerase inhibitor that also inhibits viral replication by interfering with the replication of the HCV RNA. **INDICATIONS:** Sofocure-L is indicated for: – The treatment of chronic hepatitis C virus (HCV) infection, including genotypes 1, 4, 5, and 6, in adults and pediatric patients aged 12 years and older (weighing at least 35 kg). – It may be used in combination with ribavirin for certain patients as necessary, depending on the specific HCV genotype and disease stage. **DOSAGE AND ADMINISTRATION:** – **Dosage**: The standard dosage for adults is one capsule of Sofocure-L taken once daily, with or without food. – **Duration of Treatment**: The treatment duration typically ranges from 8 to 24 weeks, depending on various factors such as genotype, treatment history, and the presence of cirrhosis. The healthcare provider will determine the appropriate treatment duration. **SIDE EFFECTS:** Sofocure-L is generally well tolerated, but side effects can occur. Common side effects may include: – Fatigue – Headache – Nausea – Insomnia – Diarrhea – Anemia (when used with ribavirin) Serious side effects are rare but may include: – Liver problems (particularly in people with pre-existing liver disease) – Severe allergic reactions **CONTRAINDICATIONS:** – Sofocure-L is contraindicated in individuals with a history of hypersensitivity to either Ledipasvir or Sofosbuvir or any component of the formulation. – The combination is not recommended for patients with decompensated liver disease (Child-Pugh Class B or C). **IMPORTANT NOTES:** – **Drug Interactions**: Sofocure-L may interact with certain medications, including those that affect liver enzymes (CYP3A) or those that are contraindicated with the components of the combination. Patients should inform their healthcare provider of all medications and supplements they are taking. – **HCV Genotype Testing**: Patients should be tested for HCV genotype and resistance prior to treatment, as this may impact treatment decisions. – **Adherence to Treatment**: It is critical to adhere to the prescribed treatment regimen to achieve the best possible outcome. ### Summary: Sofocure-L combines Ledipasvir and Sofosbuvir for the effective treatment of chronic hepatitis C virus infection. Close monitoring for side effects, adherence to prescribed treatment durations, and communication with healthcare providers regarding other medications are essential for successful therapy. Always consult with a healthcare professional for individual treatment plans based on specific patient needs.